تحسين معتمد على أجسام مضادة

عودة للموسوعة

تحسين معتمد على أجسام مضادة

In antibody-dependent enhancement (ADE), antibodies bind to both viral particles and Fc gamma receptors expressed on immune cells, increasing the likelihood that the viruses will infect those cells.

التحسين معتمد على الأجسام المضادة (Antibody-dependent enhancement، اختصاراً ADE)، وتسمى أحياناً بشكل أقل دقة تحسين المناعة immune enhancement، تحدث عندما occurs when non-neutralizing antiviral proteins facilitate virus entry into host cells, leading to increased infectivity in the cells.

There are various hypotheses on how this may happen and a likelihood that more than one mechanism exists. In one such pathway, some cells do not have the usual receptors on their surfaces that viruses use to gain entry. The antiviral proteins (i.e., the antibodies) bind to antibody Fc receptors that some of these cells have in the plasma membrane. The viruses bind to the antigen binding site at the other end of the antibody. Dengue virus can use this mechanism to infect human macrophages, causing a normally mild viral infection to become life-threatening.

An ongoing question in the COVID-19 pandemic is whether—and if so, to what extent—ADE happens in coronavirus diseases.

في عدوى ڤيروس كورونا

Non-human primates vaccinated with modified vaccinia Ankara (MVA) virus encoding full-length SARS-COV spike glycoprotein and challenged with the SARS-CoV virus had lower viral loads but suffered from acute lung injury due to antibody enhancement. A study of 29 hospitalized and subsequently recovered Coronavirus disease 2019 (COVID-19) patients after severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection found that 100% of patients had anti-spike antibodies. Moreover, anti-spike IgG correlated linearly with age and LDH (a biomarker of disease severity often elevated in cytokine release syndrome). Antibody-dependent enhancement has been observed in both severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) animal models allowing the respective viruses to enter cells expressing Fc𝛾R including myeloid lineage cells.

Moreover, antibody-dependent enhancement of acute lung injury has been documented in both SARS and MERS. Rabbits intranasally infected with MERS-COV developed a pulmonary infection characterized by viremia and perivascular inflammation of the lung. Interestingly, when challenged with MERS-COV a second time, rabbits were not protected from disease, despite having measurable antibody responses. Moreover, the rabbits developed more severe lung disease on re-exposure to MERS-COV. Similarly in SARS, mice vaccinated against SARS-COV had measurable antibody responses. However, all mice within two days of challenge developed lung pathology. The lack of protection from antibodies, and exacerbation of lung pathology has been a major challenge for coronavirus vaccine development and may similarly impact SARS-COV-2 vaccine research.


في عدوى الإنفلونزا

Prior receipt of 2008–09 TIV was associated with increased risk of medically attended pH1N1 illness during the spring–summer 2009 in Canada. The occurrence of bias (selection, information) or confounding cannot be ruled out. Further experimental and epidemiological assessment is warranted. Possible biological mechanisms and immunoepidemiologic implications are considered.

Natural infection and the attenuated vaccine induce antibodies that enhance the update of the homologous virus and H1N1 virus isolated several years later, demonstrating that a primary influenza A virus infection results in the induction of infection enhancing antibodies.

ADE was suspected in infections with influenza A virus subtype H7N9, but knowledge is limited.

في عدوى ڤيروس الدنك

The most widely known example of ADE occurs in the setting of infection with dengue virus, a single-stranded positive-polarity RNA virus of the family Flaviviridae. It causes a disease of varying severity in humans, from dengue fever (DF), which is usually self-limited, to dengue hemorrhagic fever and dengue shock syndrome, either of which may be life-threatening. It is estimated that as many as 390 million individuals are infected with dengue virus annually.

The phenomenon of ADE may be observed when a person who has previously been infected with one serotype of dengue virus becomes infected months or years later with a different serotype. In such cases, the clinical course of the disease is more severe, and these people have higher viremia compared with those in whom ADE has not occurred. This explains the observation that while primary (first) infections cause mostly minor disease (dengue fever) in children, secondary infection (re-infection at a later date) is more likely to be associated with dengue hemorrhagic fever and/or dengue shock syndrome in both children and adults.

There are four antigenically different serotypes of dengue virus (dengue virus 1–4). In 2013 a fifth serotype was reported. Infection with dengue virus induces the production of neutralizing homotypic immunoglobulin G (IgG) antibodies which provide lifelong immunity against the infecting serotype. Infection with dengue virus also produces some degree of cross-protective immunity against the other three serotypes. Neutralizing heterotypic (cross-reactive) IgG antibodies are responsible for this cross-protective immunity, which typically persists for a period of several months to a few years. These heterotypic antibody titers decrease over long time periods (4 to 20 years). While heterotypic IgG antibody titers decrease, homotypic IgG antibody titers increase over long time periods. This could be due to the preferential survival of long-lived memory B cells producing homotypic antibodies.

In addition to inducing neutralizing heterotypic antibodies, infection with dengue virus can also induce heterotypic antibodies which neutralize the virus only partially or not at all. The production of such cross-reactive but non-neutralizing antibodies could be the reason for more severe secondary infections. It is thought that by binding to but not neutralizing the virus, these antibodies cause it to behave as a "trojan horse", where it is delivered into the wrong compartment of dendritic cells that have ingested the virus for destruction. Once inside the white blood cell, the virus replicates undetected, eventually generating very high virus titers which cause severe disease.

A study conducted by Modhiran et al. attempted to explain how non-neutralizing antibodies down regulate the immune response in the host cell through the Toll-like receptor signaling pathway. Toll-like receptors are known to recognize extra- and intracellular viral particles and to be a major basis of the cytokines production. In vitro experiments showed that the inflammatory cytokines and type 1 interferon production was reduced when the ADE-dengue virus complex bound to the Fc receptor of THP-1 cells. This can be explained by both a decrease of Toll-like receptorproduction and a modification of its signaling pathway. On one hand, an unknown protein induced by the stimulated Fc receptor reduces the Toll-like receptor transcription and translation, which reduce the capacity of the cell to detect viral proteins. On the other hand, many proteins (TRIF, TRAF6, TRAM, TIRAP, IKKα, TAB1, TAB2, NF-κB complex) involved in the Toll-like receptor signaling pathway are down regulated, which led to a decrease of the cytokine production. Two of them, TRIF and TRAF6, are respectively down regulated by 2 proteins SARM and TANK up regulated by the stimulated Fc receptors.

To illustrate the phenomenon of ADE, consider the following example: an epidemic of dengue fever occurred in Cuba, lasting from 1977 to 1979. The infecting serotype was dengue virus-1. This epidemic was followed by two more outbreaks of dengue fever—one in 1981 and one in 1997; dengue virus-2 was the infecting serotype in both of these later epidemics. 205 cases of dengue hemorrhagic fever and dengue shock syndrome occurred during the 1997 outbreak, all in people older than 15 years. All but three of these cases were demonstrated to have been previously infected by the dengue virus-1 serotype during the epidemic of 1977–1979. Furthermore, people who had been infected with dengue virus-1 during the 1977-79 outbreak and secondarily infected with dengue virus-2 in 1997 had a 3-4 fold increased probability of developing severe disease than those secondarily infected with dengue virus-2 in 1981. This scenario can be explained by the presence of neutralizing heterotypic IgG antibodies in sufficient titers in 1981, the titers of which had decreased by 1997 to the point where they no longer provided significant cross-protective immunity.


في عدوى ڤيروس HIV-1

ADE of infection has also been reported in HIV. Like dengue virus, non-neutralizing level of antibodies have been found to enhance the viral infection through interactions of complement system and receptors. The increase in infection has been reported to be over 350 fold which is comparable to ADE in other viruses like dengue virus. ADE in HIV can be complement mediated or Fc receptor mediated. Complements in presence of HIV-1 positive sera have been found to enhance the infection of MT-2 T-cell line. The Fc-receptor mediated enhancement was reported when HIV infection was enhanced by sera from HIV-1 positive guinea pig enhanced the infection of peripheral blood mononuclear cells without the presence of any complements. Complement component receptors CR2, CR3 and CR4 have been found to mediate this Complement-mediated enhancement of infection. The infection of HIV-1 leads to activation of complements fragments of these complements can assist viruses with infection by facilitating viral interactions with host cells that express complement receptors. The deposition of complement on the virus brings the gp120 protein close to CD4 molecules on the surface of the cells, thus leading to facilitated viral entry. Viruses pre-exposed to non-neutralizing complement system have also been found to enhance infections in interdigitating dendritic cells. Opsonized viruses have not only shown enhanced entry but also favorable signalling cascades for HIV replication in interdigitating dendritic cells. HIV-1 has also showed enhancement of infection in HT-29 cells when the viruses were pre-opsonized with complements C3 and C9 in seminal fluid. This enhanced rate of infection was almost 2 times greater than infection of HT-29 cells with virus alone. Subramanian et al., reported that almost 72% of serum samples out of 39 HIV positive individuals contained complements that were known to enhance the infection. They also suggested that presence of neutralizing antibody or antibody-dependent cellular cytotoxicity-mediating antibodies in the serum contains infection-enhancing antibodies. The balance between the neutralizing antibodies and infection-enhancing antibodies changes as the disease progresses. During advanced stages of disease the proportion of infection-enhancing antibodies are generally higher than neutralizing antibodies. Increase in viral protein synthesis and RNA production have been reported to occur during the complement mediated enhancement of infection. Cells that are challenged with non neutralizing levels of complements have been found have accelerated release of reverse transcriptase and the viral progeny. The interaction of anti-HIV antibodies with non-neutralizing complement exposed viruses also aid in binding of the virus and the erythrocytes which can lead to a more efficient delivery of viruses to the immune compromised organs.

ADE in HIV has raised questions about the risk of infections to volunteers who have taken subneutralizing levels of vaccine just like any other viruses that exhibit ADE. Gilbert et al., in 2005 reported that there was no ADE of infection when they used rgp120 vaccine in phase 1 and 2 trials. It has been emphasized that much research needs to be done in the field of immunity response to HIV-1, information from these studies can be used to produce a more effective vaccine.

الآلية

There are several possibilities to explain the phenomenon:

  1. A viral surface protein laced with antibodies against a virus of one serotype binds to a similar virus with a different serotype. The binding is meant to neutralize the virus surface protein from attaching to the cell, but the antibody bound to virus also binds to the receptor of the cell, the Fc-region antibody receptor FcγR. This brings the virus into close proximity to the virus-specific receptor, and the cell internalizes the virus through the normal infection route.
  2. A virus surface protein may be attached to antibodies of a different serotype, activating the classical pathway of the complement system. The complement cascade system instead binds C1Q complex attached to the virus surface protein via the antibodies, which in turn bind C1q receptor found on cells, bringing the virus and the cell close enough for a specific virus receptor to bind the virus, beginning infection.[] This mechanism has not been shown specifically for dengue virus infection, but is supposed to occur with Ebola virus infection in vitro.
  3. When an antibody to a virus is present for a different serotype, it is unable to neutralize the virus, which is then ingested into the cell as a sub-neutralized virus particle. These viruses are phagocytosed as antigen-antibody complexes, and degraded by macrophages. Upon ingestion the antibodies no longer even sub-neutralize the body due to the denaturing condition at the step for acidification of phagosome before fusion with lysosome.[] The virus becomes active and begins its proliferation within the cell.[]

انظر أيضاً

  • Original antigenic sin
  • Other ways in which antibodies can (unusually) make an infection worse instead of better
    • Blocking antibody, which can be either good or bad, depending on circumstances
    • Hook effect, most relevant to in vitro tests but known to have some in vivo relevances


المصادر

  1. ^ Dimmock NJ, Easton AJ, Leppard K (2007). Introduction to modern virology. Malden, MA: Blackwell Pub. p. 65. ISBN .
  2. ^ Tetro JA (March 2020). "Is COVID-19 receiving ADE from other coronaviruses?". Microbes and Infection. 22 (2): 72–73. doi:10.1016/j.micinf.2020.02.006. PMC 7102551 Check |pmc= value (help). PMID 32092539 Check |pmid= value (help).
  3. ^ Liu L, et al. (2019). "Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection". JCI Insight.CS1 maint: display-authors (link)
  4. ^ Jiang H, et al. (2020). "Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray". Medxriv Pre-Print.CS1 maint: display-authors (link)
  5. ^ Wan Y, et al. (2020). "Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry". Journal of Virology.CS1 maint: display-authors (link)
  6. ^ Houser KV, et al. (2017). "Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody". PLOS Pathogens. 13: e1006565. doi:10.1371/journal.ppat.1006565. PMC 5574614. PMID 28817732.CS1 maint: display-authors (link)
  7. ^ Tseng C, et al. (2012). "Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus". PLOS One. 7: e35421. doi:10.1371/journal.pone.0035421.CS1 maint: display-authors (link)
  8. ^ Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. (April 2010). "Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada". PLOS Medicine. 7 (4): e1000258. doi:10.1371/journal.pmed.1000258. PMC 2850386. PMID 20386731.
  9. ^ Gotoff R, Tamura M, Janus J, Thompson J, Wright P, Ennis FA (January 1994). "Primary influenza A virus infection induces cross-reactive antibodies that enhance uptake of virus into Fc receptor-bearing cells". The Journal of Infectious Diseases. 169 (1): 200–3. doi:10.1093/infdis/169.1.200. PMID 8277183.
  10. ^ Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, et al. (April 2008). "Role of dendritic cells in antibody-dependent enhancement of dengue virus infection". Journal of Virology. 82 (8): 3939–51. doi:10.1128/JVI.02484-07. PMC 2292981. PMID 18272578.
  11. ^ Ambuel Y, Young G, Brewoo JN, Paykel J, Weisgrau KL, Rakasz EG, et al. (15 Sep 2014). "A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates". Frontiers in Immunology. 5 (2014): 263. doi:10.3389/fimmu.2014.00263. PMC 4046319. PMID 24926294.
  12. ^ Guzman MG, Vazquez S (December 2010). "The complexity of antibody-dependent enhancement of dengue virus infection". Viruses. 2 (12): 2649–62. doi:10.3390/v2122649. PMC 3185591. PMID 21994635.
  13. ^ King CA, Anderson R, Marshall JS (August 2002). "Dengue virus selectively induces human mast cell chemokine production". Journal of Virology. 76 (16): 8408–19. doi:10.1128/JVI.76.16.8408-8419.2002. PMC 155122. PMID 12134044.
  14. ^ Normile D (2013). "Tropical medicine. Surprising new Dengue virus throws a spanner in disease control efforts". Science. 342 (6157): 415. Bibcode:2013Sci...342..415N. doi:10.1126/science.342.6157.415. PMID 24159024.
  15. ^ Alvarez G, Piñeros JG, Tobón A, Ríos A, Maestre A, Blair S, Carmona-Fonseca J (October 2006). "Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia". The American Journal of Tropical Medicine and Hygiene. 75 (4): 605–9. doi:10.4269/ajtmh.2006.75.605. PMID 17038680.
  16. ^ Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S, et al. (February 2007). "Neutralizing antibodies after infection with dengue 1 virus". Emerging Infectious Diseases. 13 (2): 282–6. doi:10.3201/eid1302.060539. PMC 2725871. PMID 17479892.
  17. ^ Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (May 2007). "Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention". Proceedings of the National Academy of Sciences of the United States of America. 104 (22): 9422–7. Bibcode:2007PNAS..104.9422G. doi:10.1073/pnas.0703498104. PMC 1868655. PMID 17517625.
  18. ^ Peluso R, Haase A, Stowring L, Edwards M, Ventura P (November 1985). "A Trojan Horse mechanism for the spread of visna virus in monocytes". Virology. 147 (1): 231–6. doi:10.1016/0042-6822(85)90246-6. PMID 2998068.
  19. ^ Chen YC, Wang SY (October 2002). "Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide". Journal of Virology. 76 (19): 9877–87. doi:10.1128/JVI.76.19.9877-9887.2002. PMC 136495. PMID 12208965.
  20. ^ Witayathawornwong P (January 2005). "Fatal dengue encephalitis" (PDF). The Southeast Asian Journal of Tropical Medicine and Public Health. 36 (1): 200–2. PMID 15906668. Archived from the original (PDF) on 2011-07-24.
  21. ^ Rodenhuis-Zybert IA, Wilschut J, Smit JM (August 2010). "Dengue virus life cycle: viral and host factors modulating infectivity". Cellular and Molecular Life Sciences. 67 (16): 2773–86. doi:10.1007/s00018-010-0357-z. PMID 20372965.
  22. ^ Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. (December 2010). "Dengue: a continuing global threat". Nature Reviews. Microbiology. 8 (12 Suppl): S7–16. doi:10.1038/nrmicro2460. PMC 4333201. PMID 21079655.
  23. ^ Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. (May 2010). "Cross-reacting antibodies enhance dengue virus infection in humans". Science. 328 (5979): 745–8. Bibcode:2010Sci...328..745D. doi:10.1126/science.1185181. PMC 3837288. PMID 20448183.
  24. ^ Modhiran N, Kalayanarooj S, Ubol S (December 2010). "Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse". PLOS Neglected Tropical Diseases. PLOS ONE. 4 (12): e924. doi:10.1371/journal.pntd.0000924. PMC 3006139. PMID 21200427.
  25. ^ Guzman MG (2000). "Dr. Guzman et al. Respond to Dr. Vaughn". American Journal of Epidemiology. 152 (9): 804. doi:10.1093/aje/152.9.804.
  26. ^ Willey S, Aasa-Chapman MM, O'Farrell S, Pellegrino P, Williams I, Weiss RA, Neil SJ (March 2011). "Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection". Retrovirology. 8: 16. doi:10.1186/1742-4690-8-16. PMC 3065417. PMID 21401915.
  27. ^ Levy JA (2007). HIV and the pathogenesis of AIDS. Wiley-Blackwell. p. 247. ISBN .
  28. ^ Yu Q, Yu R, Qin X (September 2010). "The good and evil of complement activation in HIV-1 infection". Cellular & Molecular Immunology. 7 (5): 334–40. doi:10.1038/cmi.2010.8. PMC 4002684. PMID 20228834.
  29. ^ Gras GS, Dormont D (January 1991). "Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line". Journal of Virology. 65 (1): 541–5. doi:10.1128/JVI.65.1.541-545.1991. PMC 240554. PMID 1845908.
  30. ^ Bouhlal H, Chomont N, Réquena M, Nasreddine N, Saidi H, Legoff J, et al. (January 2007). "Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner". Journal of Immunology. 178 (2): 1086–95. doi:10.4049/jimmunol.178.2.1086. PMID 17202372.
  31. ^ Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H (September 2002). "Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells". Journal of Immunology. 169 (6): 3301–6. doi:10.4049/jimmunol.169.6.3301. PMID 12218150.
  32. ^ Subbramanian RA, Xu J, Toma E, Morisset R, Cohen EA, Menezes J, Ahmad A (June 2002). "Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients". Journal of Clinical Microbiology. 40 (6): 2141–6. doi:10.1128/JCM.40.6.2141-2146.2002. PMC 130693. PMID 12037078.
  33. ^ Beck Z, Prohászka Z, Füst G (June 2008). "Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development". Vaccine. 26 (24): 3078–85. doi:10.1016/j.vaccine.2007.12.028. PMC 7115406 Check |pmc= value (help). PMID 18241961.
  34. ^ Robinson WE, Montefiori DC, Mitchell WM (April 1990). "Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors". Virology. 175 (2): 600–4. doi:10.1016/0042-6822(90)90449-2. PMID 2327077.
  35. ^ Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, et al. (March 2005). "Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase ثلاثة HIV-1 preventive vaccine trial". The Journal of Infectious Diseases. 191 (5): 666–77. doi:10.1086/428405. PMID 15688279.
  36. ^ Takada A, Kawaoka Y (2003). "Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications". Reviews in Medical Virology. 13 (6): 387–98. doi:10.1002/rmv.405. PMID 14625886.
  37. ^ Takada A, Feldmann H, Ksiazek TG, Kawaoka Y (July 2003). "Antibody-dependent enhancement of Ebola virus infection". Journal of Virology. 77 (13): 7539–44. doi:10.1128/JVI.77.13.7539-7544.2003. PMC 164833. PMID 12805454.
تاريخ النشر: 2020-06-09 08:52:33
التصنيفات: CS1 errors: PMC, CS1 errors: PMID, CS1 maint: display-authors, Articles with short description, All articles with unsourced statements, Articles with unsourced statements from July 2008, Articles with invalid date parameter in template, All pages needing cleanup, مقالات بالمعرفة تحتاج توضيح from February 2009, Articles with unsourced statements from June 2007, جهاز المناعة

مقالات أخرى من الموسوعة

سحابة الكلمات المفتاحية، مما يبحث عنه الزوار في كشاف:

آخر الأخبار حول العالم

كيف فشل نصف الحراكة في الوصول إلى اسبانيا بعد زيارة سانشيز للمغرب

المصدر: الأيام 24 - المغرب التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:18:06
مستوى الصحة: 71% الأهمية: 73%

بلاغ هام إلى الحجاج المغاربة

المصدر: أخبارنا المغربية - المغرب التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:17:39
مستوى الصحة: 52% الأهمية: 67%

حكم من أدرك صلاة الجماعة متأخرًا.. الأزهر يوضح

المصدر: بوابة أخبار اليوم - مصر التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:17:53
مستوى الصحة: 48% الأهمية: 64%

«التاجر الأمين».. موضوع خطبة أول جمعة من شوال 

المصدر: بوابة أخبار اليوم - مصر التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:17:55
مستوى الصحة: 49% الأهمية: 51%

«الرعاية في ظل متغيرات العصر».. دورة تدريبية للكهنة بمعهد الرعاية

المصدر: بوابة أخبار اليوم - مصر التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:17:51
مستوى الصحة: 49% الأهمية: 52%

الأوقاف: تجهيز 600 ساحة من الملحقة بالمساجد الكبرى لـ«صلاة عيد الفطر»

المصدر: بوابة أخبار اليوم - مصر التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:17:49
مستوى الصحة: 58% الأهمية: 53%

بين 800 و1700 درهم.. الأساتذة غاضبون إثر اقتطاعات طالت أجورهم

المصدر: الأيام 24 - المغرب التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:18:03
مستوى الصحة: 60% الأهمية: 74%

حاتم عمور: وحيد حاليلوزيتش خاصو يمشي

المصدر: راديو مارس - المغرب التصنيف: رياضة
تاريخ الخبر: 2022-04-29 18:18:17
مستوى الصحة: 45% الأهمية: 50%

تناول "المقلوبة" في الأقصى .. سبب آخر لملاحقة المقدسيين

المصدر: الإمارات اليوم - الإمارات التصنيف: مجتمع
تاريخ الخبر: 2022-04-29 18:18:26
مستوى الصحة: 45% الأهمية: 64%

محلل جزائري يتهم الدبوز بإقصاء الخضر من مونديال قطر

المصدر: راديو مارس - المغرب التصنيف: رياضة
تاريخ الخبر: 2022-04-29 18:18:18
مستوى الصحة: 60% الأهمية: 67%

باملاك يحكم لقاء الذهاب بين الأهلي ووفاق سطيف وسيكازوي حكم VAR

المصدر: الأهلى . كوم - مصر التصنيف: رياضة
تاريخ الخبر: 2022-04-29 18:17:43
مستوى الصحة: 39% الأهمية: 45%

تطورات اعتقال “طلبة البوليساريو” المدججين بالمناجل في أكادير

المصدر: الأيام 24 - المغرب التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:18:04
مستوى الصحة: 71% الأهمية: 72%

الخارجية تثمن دور إبراهيم مياكي خلال توليه رئاسة وكالة النيبادً

المصدر: بوابة أخبار اليوم - مصر التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:17:52
مستوى الصحة: 59% الأهمية: 50%

مفتي الجمهورية: تقبيل يد الصالحين «احتراما وتبركا» من الأخلاق الحميدة

المصدر: بوابة أخبار اليوم - مصر التصنيف: سياسة
تاريخ الخبر: 2022-04-29 18:17:50
مستوى الصحة: 51% الأهمية: 54%

تحميل تطبيق المنصة العربية